Skip to search.
 TSX Up 0.23% TSX Ventures Down 0.25%

More On ELN

Quotes

Charts

News & Info

Company

Analyst Coverage

Ownership

  • Major Holders
  • Insider Transactions
  • Insider Roster

Financials

  • Income Statement
  • Balance Sheet
  • Cash Flow

(ELN)

-NYSE
18.12 Up 0.20(1.12%) Dec 18, 3:59PM EST - Nasdaq Real Time Price
Add to Portfolio
Prev Close:N/A
Open:18.12
Bid:N/A
Ask:N/A
1y Target Est:16.30
Beta:0.56
Next Earnings Date:N/A
Day's Range:17.91 - 18.20
52wk Range:0.20 - 18.20
Volume:10,365,152
Avg Vol (3m):N/A
Market Cap:N/A
P/E (ttm):4.07
EPS (ttm):4.45
Div & Yield:N/A (N/A)
Quotes delayed, except where indicated otherwise. Currency in .

Key Statistics

Forward P/E (1 yr):N/A
P/S (ttm):N/A
Ex-Dividend Date:N/A

Analysts

Annual EPS Est () :N/A
Quarterly EPS Est () :N/A
Mean Recommendation*:N/A
PEG Ratio (5 yr expected):N/A

* (Strong Buy) 1.0 - 5.0 (Sell)

Analyst Opinion | Estimates

Business Summary

Elan Corporation, plc operates as a biotechnology company in the United States, Ireland, and internationally. The company primarily develops ELND005, an orally bioavailable small molecule in Phase II clinical trial being investigated for multiple ... View More
Your browser doesn't support canvas
SETTINGS
Scrolling
Speed
Display
Price
Submit Feedback